))
Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE
Manage episode 352279466 series 3428257
Innhold levert av Exagen Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Exagen Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
What is the Type 1 vs Type 2 Lupus Model? How does it shape the care and management of lupus patients? And what impact does it have on the future of drug development to address Type 2 symptoms?
Join Exagen and Dr. Jen Rogers, Director of the Duke Lupus Clinic as she breaks down the abstract, The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE, how the study came to be, and its clinical importance to both providers and patients.
3 episoder
Del
